Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients

Journal of Psychopharmacology

Volumn 24, Issue 7, 2010, Pages 1115-1120

  Du, J ^a,b   Zhang, A ^a,c   Wang, L ^a,c   Xuan, J ^a,c   Yu, L ^a,c   Che, R ^a,c   Li, X ^a,c   Gu, N ^d   Lin, Z ^d   Feng, G ^d   Xing, Q ^a,c   He, L ^a,c  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF PLANNED PARENTHOOD RESEARCH   (China)

^c Chinese Academy of Sciences   (China)

^d SHANGHAI MENTAL HEALTH CENTER   (China)

Author keywords

9 hydroxyrisperidone; Clinical response; CYP3A4; Risperidone; Schizophrenia

Indexed keywords

CYTOCHROME P450 3A; PALIPERIDONE; RISPERIDONE;

ADULT; ARTICLE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; EVENING DOSAGE; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PSYCHIATRIC STATUS RATING SCALES; PYRIMIDINES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; YOUNG ADULT;

EID: 77953764539     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881109104932     Document Type: Article

References (28)

1. Ahmadi, KR, Weale, ME, Xue, ZY, Soranzo, N., Yarnall, DP, Briley, JD, et al. (2005) A single-nucleotide polymorphism tagging set for human drug metabolism and transport. Nat Genet 37: 84-89.
2. Csernansky, JG, Mahmoud, R., Brenner, R. (2002) A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346: 16-22.
3. Davis, JM, Matalon, L., Watanabe, MD, Blake, L., Metalon, L. (1994) Depot antipsychotic drugs: place in therapy. Drugs 47: 741-773.
4. de Leon, J. (2007) The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultra-rapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19. J Clin Psychopharmacol 27: 241-245.
5. de Leon, J., Susce, MT, Pan, RM, Fairchild, M., Koch, WH, Wedlund, PJ (2005) The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 66: 15-27.
6. DeVane, CL, Nemeroff, CB (2001) An evaluation of risperidone drug interactions. J Clin Psychopharmacol 21: 408-416.
7. Fang, J., Bourin, M., Baker, GB (1999) Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol 359: 147-151.
8. Faul, F., Erdfelder, E., Lang, AG, Buchner, A. (2007) G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39: 175-191.
9. Flaum, M., Amador, X., Gorman, J., Bracha, HS, Edell, W., McGlashan, T., et al. (1997) DSM-IV Sourcebook. Washington, DC: American Psychiatric Association.
10. Fukushima-Uesaka, H., Saito, Y., Watanabe, H., Shiseki, K., Saeki, M., Nakamura, T., et al. (2004) Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum Mutat 23: 100.
11. Huang, ML, Van Peer, A., Woestenborghs, R., De Coster, R., Heykants, J., Jansen, AA, et al. (1993) Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 54: 257-268.
12. Du, J., Xing, Q., Xu, L., Xu, M., Shu, A., Shi, Y., et al. (2006) Systematic screening for polymorphisms in the CYP3A4 gene in a Chinese population. Pharmacogenomics 7: 831-841.
13. Kane, JM (1996) Schizophrenia. N Engl J Med 334: 34-41.
14. Kay, SR, Fiszbein, A., Opler, LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276.
15. Leucht, S., Barnes, TR, Kissling, W., Engel, RR, Correll, C., Kane, JM (2003) Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 160: 1209-1222.
16. Lieberman, JA (1996) Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. J Clin Psychiatry 57 (Suppl. 11). 68-71.
17. Mannens, G., Huang, ML, Meuldermans, W., Hendrickx, J., Woestenborghs, R., Heykants, J. (1993) Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos 21: 1134-1141.
18. Mauri, MC, Laini, V., Boscati, L., Rudelli, R., Salvi, V., Orlandi, R., et al. (2001) Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels. Eur Psychiatry 16: 57-63.
19. Megens, AA, Awouters, FH, Schotte, A., Meert, TF, Dugovic, C., Niemegeers, CJ, et al. (1994) Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl) 114: 9-23.
20. Olesen, OV, Licht, RW, Thomsen, E., Bruun, T., Viftrup, JE, Linnet, K. (1998) Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther Drug Monit 20: 380-384.
21. Robinson, D., Woerner, MG, Alvir, JM, Bilder, R., Goldman, R., Geisler, S., et al. (1999) Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56: 241-247. (Pubitemid 29125132)
22. Schotte, A., Janssen, PF, Gommeren, W., Luyten, WH, Van Gompel, P., Lesage, AS, et al. (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 124: 57-73.
23. Schulz, SC, Findling, RL, Wise, A., Friedman, L., Kenny, J. (1998) Child and adolescent schizophrenia. Psychiatr Clin North Am 21: 43-56.
24. Stephens, M., Scheet, P. (2005) Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet 76: 449-462.
25. Stephens, M., Smith, NJ, Donnelly, P. (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68: 978-989.
26. van Beijsterveldt, LE, Geerts, RJ, Leysen, JE, Megens, AA, Van den Eynde, HM, Meuldermans, WE, et al. (1994) Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology (Berl) 114: 53-62.
27. Wang, L., Yu, L., Zhang, AP, Fang, C., Du, J., Gu, NF, et al. (2007) Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia. J Psychopharmacol 21: 837-842.
28. Yasui-Furukori, N., Hidestrand, M., Spina, E., Facciola, G., Scordo, MG, Tybring, G. (2001) Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos 29: 1263-1268.